RC
PTLA

Randolph Company’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Randolph Company’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-125,200
Closed -$4.91M – 43
2017
Q1 		$4.91M Sell
125,200
-200
-0.2% -$6.37K 0.94% 30
2016
Q4 		$2.81M Sell
125,400
-50
-0% -$977 0.58% 35
2016
Q3 		$2.85M Buy
+125,450
New +$2.94M 0.72% 27

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Randolph Company's PTLA Position: Q2 2017 in Review

Randolph Company sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2017, closing a stake of 125,200 shares — an estimated $4.91M sold.

Randolph Company first reported a position in PTLA in Q3 2016 and held it in 3 quarters. The position peaked at $4.91M in Q1 2017. 206 funds tracked by Wall St. Rank hold PTLA as of Q2 2017.

  • Randolph Company reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Randolph Company sold 125,200 Portola Pharmaceuticals, Inc. shares in Q2 2017, an estimated $4.91M.
  • Randolph Company first reported a position in Portola Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
  • Randolph Company's Portola Pharmaceuticals, Inc. position peaked at $4.91M in Q1 2017.
  • 206 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2017.

Based on Randolph Company's 13F filing for Q2 2017, filed 13 Jul 2017.